Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation's perspective.
Keywords: CAR-T in developing economies; autologous CAR-T; cellular therapy; decentralised manufacturing; manufacturing models.
Copyright © 2022 Ramakrishnan, Kumar, Datta, Radhakrishnan, Nair and Chandy.